Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cerevel Therapeutics Holdings, Inc. - Common Stock (NQ:CERE)

44.96 UNCHANGED
Last Price Updated: 4:15 PM EDT, Jul 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 44.96
Bid (Size) 44.97 (20)
Ask (Size) 44.98 (146)
Prev. Close 44.96
Today's Range 44.96 - 44.96
52wk Range 40.19 - 44.96
Shares Outstanding 156,832,992
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CERE Investors Have the Opportunity to Lead the Cerevel Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
From Faruqi & Faruqi, LLP
Via Business Wire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire

Performance

YTD
N/A
N/A
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
N/A
N/A
1 Year
+9.5%
+9.5%

More News

Read More
CERE Deadline: Rosen Law Firm Urges Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
From Rosen Law Firm
Via Business Wire
Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
Faruqi & Faruqi Reminds Cerevel Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - CERE
From Faruqi & Faruqi LLP
Via GlobeNewswire
Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
ROSEN, A TOP RANKED LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE
From The Rosen Law Firm PA
Via GlobeNewswire
Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE
From The Rosen Law Firm PA
Via GlobeNewswire
Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
Robbins LLP Reminds CERE Stockholders With Large Losses to Contact the Firm for Information About the Class Action Lawsuit on Behalf of Former Cerevel Therapeutics Holdings, Inc. Shareholders
From Robbins LLP
Via GlobeNewswire
Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
CEREVEL ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Cerevel Therapeutics Holdings, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Rosen Law Firm Urges Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) Stockholders to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
Cerevel Therapeutics Holdings, Inc. Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit on Behalf of Former CERE Shareholders
From Robbins LLP
Via GlobeNewswire
Entwistle & Cappucci LLP Files a Securities Class Action Against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC and Pfizer, Inc.
From Entwistle & Cappucci LLP
Via Business Wire
Entwistle & Cappucci LLP is Investigating Potential Federal Securities Law Violations in Connection with Cerevel Therapeutics Holdings, Inc. (CERE)
From Entwistle & Cappucci LLP
Via Business Wire
CERE Investors Have Opportunity to Join Cerevel Therapeutics Holdings, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
CERE Investors Have the Opportunity to Join Investigation of Cerevel Therapeutics Holdings, Inc. with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
CEREVEL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) Buyout and Encourages Investors to Contact the Firm
From Kaskela Law LLC
Via Business Wire
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga

Frequently Asked Questions

Is Cerevel Therapeutics Holdings, Inc. - Common Stock publicly traded?
Yes, Cerevel Therapeutics Holdings, Inc. - Common Stock is publicly traded.
What exchange does Cerevel Therapeutics Holdings, Inc. - Common Stock trade on?
Cerevel Therapeutics Holdings, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cerevel Therapeutics Holdings, Inc. - Common Stock?
The ticker symbol for Cerevel Therapeutics Holdings, Inc. - Common Stock is CERE on the Nasdaq Stock Market
What is the current price of Cerevel Therapeutics Holdings, Inc. - Common Stock?
The current price of Cerevel Therapeutics Holdings, Inc. - Common Stock is 44.96
When was Cerevel Therapeutics Holdings, Inc. - Common Stock last traded?
The last trade of Cerevel Therapeutics Holdings, Inc. - Common Stock was at 07/31/24 04:15 PM ET
What is the market capitalization of Cerevel Therapeutics Holdings, Inc. - Common Stock?
The market capitalization of Cerevel Therapeutics Holdings, Inc. - Common Stock is 7.05B
How many shares of Cerevel Therapeutics Holdings, Inc. - Common Stock are outstanding?
Cerevel Therapeutics Holdings, Inc. - Common Stock has 7B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.